RECRUITINGOBSERVATIONAL
Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based
About This Trial
Prospective, open, non-interventional, multi-center clinical registry study with the aim to establish a comprehensive research platform reflecting the real-world treatment landscape for recurrent/metastatic head and neck tumor patients.
Who May Be Eligible (Plain English)
Who May Qualify:
- Age ≥ 18 years
- Able to understand and willing to sign written willing to sign a consent form
- diagnosed by tissue sample (biopsy-confirmed) squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx or larynx)
- Patients not amenable for curative treatment who receive palliative systemic treatment or best supportive care
- willing to sign a consent form no later than four weeks after start of first-line palliative systemic treatment. For patients receiving "best supportive care only": no later than six weeks after diagnosis/recurrence or metastatic disease
Who Should NOT Join This Trial: none
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Age ≥ 18 years
* Able to understand and willing to sign written informed consent
* Histologically or cytologically confirmed squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx or larynx)
* Patients not amenable for curative treatment who receive palliative systemic treatment or best supportive care
* Informed consent no later than four weeks after start of first-line palliative systemic treatment. For patients receiving "best supportive care only": no later than six weeks after diagnosis/recurrence or metastatic disease
Exclusion Criteria: none
Treatments Being Tested
OTHER
data collection
Demography, Social history, Riskfactors, Relevant medical history, Oncological family history, Disease \& treatment history, Molecular Pathology and Results, Treatment data, Response data, progession free survial, overall survival.
Locations (2)
Universitätsklinikum Essen
Essen, Germany
Onkologie/Studienzentrum am Raschplatz GbR
Hanover, Germany